News about 'r&d'

This week, we are highlighting two articles published online in the Journal of Infectious Diseases in March. The first article by Coxon, et al., looks at the benefits and limitations of the two main approaches to compound discovery for TB, target-based and phenotypic-based. The second article by...

Click here to access publication. The WGND Strategic Plan 2011-2015 is an update of the “New Drugs” section of the Global Plan to Stop TB: 2011-2015 . It describes the progress, gaps, and vision of the WGND and the TB drug development field as a whole. Since its inception, the WGND has served as a...

The 243rd American Chemistry Society National Meeting and Exposition is being held in San Diego, California, from March 26 to March 29. There are several presentations on tuberculosis. Here are the abstracts of a few of the talks. The first item received news coverage and discusses two approved...

Click here to get more info. Saturday, March 24, is officially World TB Day but there has been a stream of activities, publications, news and messages to let the world not forget about this major infectious disease killer that claims millions of lives each year. Events On March 7 and 13, the CORE...

The audience takes in the promise of the NC--002 trial. During the “Cure All: A briefing on the status of the most promising new TB drugs research” sponsored by the Critical Path to New TB Drug Regimens (CPTR) on Monday, March 19, Dr. Mel Spigelman, CEO & President, of TB Alliance announced the...

At the 19th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, results on the Thibela TB preventative therapy trial in South Africa gold miners was presented with mixed outcomes. On one hand, the number of cases in miners in the experimental group who screened negative for...

Dr. Tawanda Gumbo Summary: Dr. Tawanda Gumbo , an associate professor at the The University of Texas Southwestern Medical Center, recently published a paper in the Journal of Infectious Diseases entitled “Multidrug-resistant tuberculosis not due to noncompliance but to between-patient...

Grzegorzewicz AE, Pham H, Gundi VA, Scherman MS, North EJ, Hess T, Jones V, Gruppo V, Born SE, Korduláková J, Chavadi SS, Morisseau C, Lenaerts AJ, Lee RE, McNeil MR, Jackson M. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat Chem Biol. 2012 Feb 19...

Tobin DM, Roca FJ, Oh SF, McFarland R, Vickery TW, Ray JP, Ko DC, Zou Y, Bang ND, Chau TT, Vary JC, Hawn TR, Dunstan SJ, Farrar JJ, Thwaites GE, King M, Serhan CN, Ramakrishnan L. Host Genotype-Specific Therapies Can Optimize the Inflammatory Response to Mycobacterial Infections. Cell. 2012 Feb 3;...

On November 17 and 18, a TB Clinical Trials Consultants Meeting was held at St. George’s, University of London. The meeting was organized by CDC , CPTR , INTERTB , NIH , and TB Alliance . The meeting was convened to catalog expert opinion on the conduct of Phase 2 and Phase 3 clinical trials in...

Reddy VM, Dubuisson T, Einck L, Wallis RS, Jakubiec W, Ladukto L, Campbell S, Nacy CA. SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro. J Antimicrob Chemother. 2012 Jan 17. [Epub ahead of print] In this week’s article, we look at two drugs in our Global TB Drug Pipeline...

Dr. Yossef Av-Gay Summary: Dr. Yossef Av-Gay , a professor in the Division of Infectious Diseases at the University of British Columbia, recently published a paper in the Proceedings of the National Academy of Sciences (PNAS) entitled “ Mycobacterium tuberculosis protein tyrosine phosphatase (PtpA...

Click here for full report. Today, the fourth annual G-FINDER survey tracking funding for research and development of neglected disease technologies was released. This year’s report shows that funding for product development is on the decline and product development partnerships (PDPs) have been...

Napier RJ, Rafi W, Cheruvu M, Powell KR, Zaunbrecher MA, Bornmann W, Salgame P, Shinnick TM, Kalman D. Imatinib-Sensitive Tyrosine Kinases Regulate Mycobacterial Pathogenesis and Represent Therapeutic Targets against Tuberculosis . Cell Host Microbe. 2011 Nov 17;10(5):475-85. This week’s article...

Gyanu Lamicchane Summary: Microbial geneticist Dr. Gyanu Lamichhane of the Johns Hopkins Center for Tuberculosis Research is one of 49 recipients of the New Innovator Award, which is given to promising scientists in the early stages of their careers and is supported directly with $1.5 million in...